The disconnect between Valneva’s stock price and the analyst consensus has rarely been wider. Twelve analysts carry an average price target of €6.16 — nearly three times the current level — yet the shares keep sliding. On Wednesday, the stock punched through the key €2.26 support level that had underpinned it for months, settling at €2.23. By Thursday, it had slipped further to €2.21, hovering just above the 52-week low.
The slide has been relentless. Since the start of the year, Valneva has shed 42% of its value. The 52-week high of €5.16, set in August 2025, now looks like a distant memory. The 200-day moving average sits roughly 40% above the current price — a gap that historically signals entrenched bearish momentum.
Behind the technical breakdown lies a rapidly worsening fundamental picture. First-quarter net loss ballooned to €32.1 million from €9.2 million a year earlier, as revenue collapsed 37% to €30.9 million. Weak demand for travel vaccines, compounded by geopolitical headwinds in key markets, forced management to slash its 2026 revenue guidance to a range of €135–150 million, down from the previous €145–160 million.
The response has been Draconian. Valneva plans to cut 10–15% of its global workforce and reduce operating costs by 25–35% this year. The company ended March with €105 million in cash — adequate for now, but burning fast given the widening losses.
Should investors sell immediately? Or is it worth buying Valneva?
Institutional investors have taken notice — and not in a good way. Short positions have doubled in the past month, with three funds now holding a combined 2.37% of the company’s capital. The relative strength index, which stood at 34.5 earlier in the week, has since slipped to 33.6, confirming deepening oversold conditions that have yet to trigger any meaningful bounce.
All hope rests on a single pipeline asset: the Lyme disease vaccine candidate LB6V, developed in partnership with Pfizer. The Phase 3 VALOR study showed efficacy above 70% in people aged five and older. The first pre-specified analysis missed its statistical threshold because too few Lyme cases accumulated during the study period, but the second pre-defined analysis hit the mark. Pfizer now plans to submit regulatory filings, building on the Fast-Track designation already granted by the FDA.
That filing cannot come soon enough. Every delay in the submission increases the pressure on a stock that is pricing in little else. The management team hit the road in June — first at the virtual Oddo BHF Nextcap Forum, then the BNP Paribas SMID Cap Conference in Paris, and culminating in the annual general meeting in Lyon on 25 June. Investors will demand a clear path to profitability at the AGM, but the ultimate catalyst remains out of Valneva’s hands: Pfizer’s move to file LB6V. Until that happens, the bears are running the show.
Ad
Valneva Stock: Buy or Sell?! New Valneva Analysis from June 11 delivers the answer:
The latest Valneva figures speak for themselves: Urgent action needed for Valneva investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 11.
Valneva: Buy or sell? Read more here...
